Recent Advances in the Detection and Pathophysiology of Steatotic, Alcoholic and Drug-Induced Liver Diseases

Dear Colleagues,

Chronic liver diseases (CLDs) have emerged as a leading cause of hepatic-related morbidity and mortality worldwide. Amongst these, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), alcoholic liver disease (ALD), and drug-induced liver injury (DILI) result from one or a combination of genetic, environmental, and lifestyle-associated factors, such as diet-induced obesity, metabolic dysfunction, alcohol misuse, and drug toxicity. The late detection of CLDs, owing to their insidious nature and heterogeneous pathophysiology, significantly limits the use of therapeutic options that aim to halt or reverse disease progression. A promising avenue for improved patient prognosis lies in the identification of cell-type and disease-specific biomarkers, especially those that can be detected at the early stages of disease. We invite submissions that highlight the latest advancements in pathophysiological and inflammatory mechanisms underlying CLDs (excluding those with viral or autoimmune origins). Contributions that examine novel pathogenic pathways, cellular interactions, biomarker discovery and characterisation, mixed aetiologies (e.g., MASLD-DILI), precision medicine, and the influence of lifestyle and environmental factors on CLD progression are particularly encouraged. This Special Issue aims to compile recent breakthroughs in research that will enhance the early diagnosis and targeted treatment of CLDs, paving the way for improved patient outcomes.

Dr. Leonard Nelson
Dr. Michel Kranendonk
Dr. Anabel Martinez Lyons
Dr. Francisco Esteves
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Livers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.